Pituitary disorders:

Indications for: EGRIFTA SV

For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Limitations of Use:

Long-term cardiovascular benefit and safety have not been studied. Not for use in weight loss management. No data to support improved compliance with anti-retroviral therapies in HIV (+) patients.

Adult Dosage:

Give by SC inj. Inject into abdomen, rotate inj sites. 1.4mg (0.35mL) once daily.

Children Dosage:

Not established.

EGRIFTA SV Contraindications:

Disruption of hypothalmic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumors/surgery, head irradiation, or head trauma. Active malignancy. Pregnancy.

EGRIFTA SV Warnings/Precautions:

History of treated and stable malignancies. Fluid retention. Discontinue in critically ill patients. Monitor IGF-1 levels closely; consider discontinuing if IGF-1 levels persistently elevated (eg, >3 SDS). Increased risk of impaired glucose tolerance or diabetes; monitor for changes in glucose metabolism. Monitor for worsening retinopathy in diabetic patients. Nursing mothers: not recommended.

See Also:

EGRIFTA SV Classification:

Growth hormone releasing factor analogue.

EGRIFTA SV Interactions:

Caution with concomitant drugs metabolized by CYP450 (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine). May inhibit 11β-hydroxysteroid dehydrogenase type 1; may need to increase maintenance and stress doses of glucocorticoid if needed for replacement in hypoadrenalism.

Adverse Reactions:

Arthralgia, inj site erythema/pruritus, extremity pain, peripheral edema, hyperglycemia, myalgia, carpal tunnel syndrome; glucose intolerance, hypersensitivity reactions.

Generic Drug Availability:


How Supplied:

Egrifta—60 (vials w. diluent + supplies); Egrifta SV—30 (vials w. diluent + supplies)